68GA-FAPI PET/CT IN THE STAGING OF HIGH GRADE EPITHELIAL OVARIAN CANCERS: A PILOT STUDY
- Registry ID
- FAST HOC
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- PRINCESS MARGARET CANCER CENTRE
- Start date
- 2023-07-12
- Last update
- 2022-12-30
Conditions
- EPITHELIAL OVARIAN CANCER
Related clinical trials
- A PHASE 1B/2 OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RALUDOTATUG DERUXTECAN WITH OR WITHOUT OTHER ANTICANCER INVESTIGATIONAL AGENTS IN PARTICIPANTS WITH HIGH-GRADE SEROUS EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN TUBE CANCER WHO HAVE RELAPSED AFTER PRIOR PLATINUM-BASED CHEMOTHERAPY
- A RANDOMISED, OPEN-LABEL, PHASE III STUDY OF AZD5335 VERSUS MIRVETUXIMAB SORAVTANSINE IN FR¿-HIGH AND AZD5335 VERSUS INVESTIGATOR’S CHOICE CHEMOTHERAPY IN FR¿-LOW EXPRESSING HIGH-GRADE PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER PATIENTS (TREVI-OC-01)
- A PHASE 2 OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF LUVELTAMAB TAZEVIBULIN (STRO-002) IN WOMEN WITH RELAPSED PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER (INCLUDING FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCERS) EXPRESSING FOLATE RECEPTOR ALPHA (FOLR1)
- A PHASE 3 STUDY OF RELACORILANT IN COMBINATION WITH NAB-PACLITAXEL VERSUS NAB-PACLITAXEL MONOTHERAPY IN ADVANCED, PLATINUM-RESISTANT HIGH-GRADE EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN-TUBE CANCER (ROSELLA)
- RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE 3 STUDY OF MIRVETUXIMAB SORAVTANSINE IN COMBINATION WITH BEVACIZUMAB VERSUS BEVACIZUMAB ALONE AS MAINTENANCE THERAPY FOR PATIENTS WITH FRA-HIGH RECURRENT PLATINUM-SENSITIVE EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCERS WHO HAVE NOT PROGRESSED AFTER SECOND-LINE PLATINUM-BASED CHEMOTHERAPY PLUS BEVACIZUMAB (GLORIOSA)
- MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF CARBOPLATIN PLUS MIRVETUXIMAB SORAVTANSINE FOLLOWED BY MIRVETUXIMAB SORAVTANSINE CONTINUATION IN FOLATE RECEPTOR-ALPHA POSITIVE, RECURRENT PLATINUM-SENSITIVE, HIGH-GRADE EPITHELIAL OVARIAN, PRIMARY PERITONEAL OR FALLOPIAN TUBE CANCERS FOLLOWING 1 PRIOR LINE OF PLATINUM-BASED CHEMOTHERAPY
View on source registry